Percheron TherapeuticsPERCF -0.18% Receivables Turnover is 0.00 as of Dec. 2025. The stock has 2 warning signs investors should review. Among 943 Drug Manufacturers companies, Percheron Therapeutics ranks worse than 106044.43% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Percheron Therapeutics's Revenue for the
six
months ended in Dec. 2025 was $0.00 Mil. Percheron Therapeutics's average Accounts Receivable for the
six
months ended in Dec. 2025 was $0.05 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Percheron Therapeutics Receivables Turnover Related Terms
Percheron Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Percheron Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PERCF vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Percheron Therapeutics Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Percheron Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Percheron Therapeutics (PERCF) has a Receivables Turnover of 0.00 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Percheron Therapeutics and its competitors. According to the industry distribution chart, Percheron Therapeutics ranks #999999 out of 943 companies in the Drug Manufacturers industry.
Is Percheron Therapeutics' Receivables Turnover too high?
Percheron Therapeutics' current Receivables Turnover is 0.00. Based on the distribution chart, Percheron Therapeutics ranks #999999 out of 943 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Percheron Therapeutics' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Percheron Therapeutics ranks #999999 out of 943 companies for Receivables Turnover. This places Percheron Therapeutics in the lower half of its industry. The industry median Receivables Turnover is 5.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Percheron Therapeutics and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Percheron Therapeutics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PERCF has been successfully added to your 